2018 Oncology Nursing Drug Handbook This title has been archived.
Author: Gail Wilkes, MS, APRN-BC, AOCN, Margaret Barton-Burke, PhD, RN, FAAN
Affiliation: Oncology Nursing Consultant, Kilauea, Hawaii
Publisher: Jones & Bartlett Learning
Publication Date: 2018
ISBN 10: 1284143503
ISBN 13: 9781284143508
eISBN: 9781284143515
Edition: 22nd
Affiliation: Oncology Nursing Consultant, Kilauea, Hawaii
Publisher: Jones & Bartlett Learning
Publication Date: 2018
ISBN 10: 1284143503
ISBN 13: 9781284143508
eISBN: 9781284143515
Edition: 22nd
Description:
Written especially for nurses caring for patients with cancer, the 2018 Oncology Nursing Drug Handbook uniquely expresses drug therapy in terms of the nursing process: nursing diagnoses, etiologies of toxicities, and key points for nursing assessment, intervention, and evaluation. Updated annually, this essential reference provides valuable information on effective symptom management, patient education, and chemotherapy administration.
Completely revised and updated, the 2018 Oncology Nursing Drug Handbook includes separate chapters on molecular and immunologic/biologic targeted therapies. These chapters provide fundamental reviews to assist nurses in understanding the cellular communication pathways disrupted by cancer. It also offers simplified content, attention to understanding the immune checkpoint inhibitors, new information about immunotherapy, new drugs and their indications, and updated indications and side effects for recently FDA approved drugs.
New drugs include: avelumab (Bavencio), brigatinib (Alunbrig), durvalumab (Imfinzi), enasidenib (Idhifa), metronidazole hydrochloride (Flagyl), midostaurin (Rydapt), neratinib (Nerlynx), niraparib (Zejula), olaratumab (Lartruvo), ribociclib (Kisqali), rituximab and hyaluronidase human injection (Rituxan Hycela injection), rucaparib (Rubraca), telotristat ethyl (Xermelo), and tisagenlecleucel (Kymriah).
Related Titles